Combination of Regulatory T Cells and Rapamycin as Treatment for Experimental Chronic Graft-Versus-Host Disease

    November 2013 in “ Blood ”
    Ludovic Belle, Grégory Ehx, Joan Somja, Marilène Binsfeld, Muriel Hannon, Jo Caers, Gilles Fransolet, Yves Béguin, Stéphanie Humblet-Baron, Frédéric Baron
    TLDR Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
    The study investigated the combination of regulatory T cells and rapamycin as a treatment for experimental chronic graft-versus-host disease (cGVHD). The results demonstrated that this combination therapy significantly reduced the severity of cGVHD in the experimental models. The findings suggested that regulatory T cells, when used in conjunction with rapamycin, could effectively modulate the immune response and improve outcomes in cGVHD, providing a potential therapeutic strategy for managing this condition.
    Discuss this study in the Community →